Johnson & Johnson’s Medical Affairs team is transforming strategy with data-driven insights, moving beyond traditional approaches to identify key opinion leaders, improve advisory board diversity, and enhance patient journey mapping. With H1’s analytics, they are shifting from quantity to quality in engagements, advancing health equity, and leveraging AI for smarter decision-making.
Medical content is different from promotional content – it’s all about clinical data, real-world evidence, and scientific narratives. So, as you adopt a modular strategy for your medical content, why use a promotional approach?
This article explores how Sumitomo Pharma America (SMPA) leveraged H1’s advanced data capabilities to integrate diverse insights, enhance field medical strategies, and foster cross-functional collaboration across therapeutic areas.
Take advantage of alternative impact metrics that better reflect the multidimensional nature of today’s research dissemination and consumption.
Dig into best practices for measuring the operational effectiveness of Medical Affairs teams, emphasizing the importance of establishing a strong foundation of data and metrics to demonstrate impact and value within pharmaceutical organizations.
Digital Science held a roundtable discussion with Medical Affairs leaders in Madrid in May 2024 on the topic of scientific communications strategies assessment and their success measurements for multiple stakeholders.
The MAPS Puerto Rico Roundtable hosted by Real Chemistry in March 2024 discussed the integration of digital platforms, AI, and personalized content to enhance engagement with healthcare providers (HCPs). The panel emphasized the shift towards real-time, tailored information delivery and the importance of leveraging insights from both traditional and digital sources to support effective engagement strategies while ensuring compliance.
Share of Voice used to be a numbers game to increase sales and market share. But with the advent of the digital age, Share of Voice has come to mean more than just numbers.
Drawing on insights from a roundtable of industry leaders convened by Klick at the recent MAPS conference, let’s look at how viewing the KOL holistically can lead to new avenues of engagement and more multifaceted relationships.
Addressing the critical importance of integrating robust scientific understanding into the commercial journey, pinpointing the need for medical affairs to take the helm in defining and communicating the commercial value of healthcare innovations.